The Ternary Structure of the Double-headed Arrowhead Protease Inhibitor API-A Complexed with Two Trypsins Reveals a Novel Reactive Site Conformation |
| |
Authors: | Rui Bao Cong-Zhao Zhou Chunhui Jiang Sheng-Xiang Lin Cheng-Wu Chi Yuxing Chen |
| |
Affiliation: | From the ‡Institute of Protein Research, Tongji University, Shanghai 200092, ;the §Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, and ;the ¶Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China |
| |
Abstract: | The double-headed arrowhead protease inhibitors API-A and -B from the tubers of Sagittaria sagittifolia (Linn) feature two distinct reactive sites, unlike other members of their family. Although the two inhibitors have been extensively characterized, the identities of the two P1 residues in both API-A and -B remain controversial. The crystal structure of a ternary complex at 2.48 Å resolution revealed that the two trypsins bind on opposite sides of API-A and are 34 Å apart. The overall fold of API-A belongs to the β-trefoil fold and resembles that of the soybean Kunitz-type trypsin inhibitors. The two P1 residues were unambiguously assigned as Leu87 and Lys145, and their identities were further confirmed by site-directed mutagenesis. Reactive site 1, composed of residues P5 Met83 to P5′ Ala92, adopts a novel conformation with the Leu87 completely embedded in the S1 pocket even though it is an unfavorable P1 residue for trypsin. Reactive site 2, consisting of residues P5 Cys141 to P5′ Glu150, binds trypsin in the classic mode by employing a two-disulfide-bonded loop. Analysis of the two binding interfaces sheds light on atomic details of the inhibitor specificity and also promises potential improvements in enzyme activity by engineering of the reactive sites.Protease inhibitors (PIs)4 are ubiquitously distributed in all organisms, including plants, animals, and microorganisms (1). They play vital roles in regulating their corresponding proteases, which are involved in many biological processes such as protein digestion, cell signal transmission, inflammation, apoptosis, blood coagulation, and embryogenesis (2). The clinical applications of PIs are widespread, and there is great interest in developing more potent therapeutic PIs for treating human diseases related to cancer (3), pancreatitis (4), thrombosis (5), and AIDS (6). To this end, the soybean Kunitz-type serine proteases inhibitors have been extensively studied (1, 7–11). The inhibitors of this family generally contain 170–200 residues and have two disulfide bonds. Most members have only one reactive site located in the region of residues 60–70 (7, 10, 12–14). However, a few members possess two reactive sites that simultaneously bind two protease molecules and are thus termed double-headed inhibitors (15–18). All of these inhibitors are classified into family I3 of peptidase inhibitors (19). Most members are further grouped into subfamily I3A. However, the double-headed arrowhead PIs API-A and -B are grouped in subfamily I3B because of their very low sequence similarity to other members (19). In contrast to other double-headed PIs such as the Bowman-Birk and ovomucoid inhibitors, which have two identical reactive sites that have evolved by domain shuffling and gene duplication (1, 20–25), both API-A and -B have two distinct reactive sites.API-A and -B were first purified from the tubers of Sagittaria sagittifolia (Linn) in 1979 (26). Both consist of 179 residues with three disulfide bonds and can inhibit a variety of serine proteases, including trypsin, chymotrypsin, and porcine tissue kallikrein (17, 26–28). Although the sequence identity of API-A and -B is as high as 91%, their inhibitory specificities differ. The former can bind one molecule of trypsin and one molecule of chymotrypsin, whereas the latter can simultaneously bind two molecules of trypsin (26). The two P1 residues of the reactive sites of API-A and -B were first predicted to be Lys44 and Arg76 based on their surrounding sequences, which are similar to those of the reactive sites of bovine pancreas trypsin inhibitor and soybean Kunitz trypsin inhibitor (29). However, their identities were later revised to Arg76 and Leu87 (for API-A) or Lys87 (for API-B) based on results from sited-directed mutagenesis studies (30).To clarify these controversies, we solved the crystal structure of API-A in complex with two molecules of bovine trypsin. To the best of our knowledge, this is the first report on the three-dimensional structure of the double-headed Kunitz-type trypsin inhibitor in complex with two molecules of protease. On the basis of this structure, the two P1 residues have now been identified as Leu87 and Lys145 for reactive site 1 (RS1) and 2 (RS2), respectively. The results were further confirmed by site-directed mutagenesis. It was earlier shown that the first P1 residue Leu87 interacts preferentially with chymotrypsin (30). In our structure, Leu87 is snugly embedded in the S1 pocket of trypsin, as a consequence of the broad interface contributed by the surrounding residues. Comprehensive analyses of the two reactive site interfaces have provided functional insights into the novel inhibitory patterns of this unique double-headed protease inhibitor. |
| |
Keywords: | |
|
|